Drug Trial Radar · NCT01313676
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16,568
Actual
Start
Jan 25, 2011
Primary completion
Jul 15, 2015
Study completion Jul 15, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterolDrug
100/25mcg given once daily via novel dry powder inhaler
fluticasone furoateDrug
100mcg given once daily via novel dry powder inhaler
vilanterolDrug
25mcg given once daily via novel dry powder inhaler
PlaceboOther
placebo comparator once daily via novel dry powder inhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End DateTime frame: From the date of randomization until date of death due to any cause (average of 2 study years)
Locations
1,611 sites in 44 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Andalusia, Alabama
GSK Investigational Site
Athens, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Montgomery, Alabama
GSK Investigational Site
Montgomery, Alabama
GSK Investigational Site
Muscle Shoals, Alabama
GSK Investigational Site
Ozark, Alabama
GSK Investigational Site
Pell City, Alabama
GSK Investigational Site
Tuscumbia, Alabama
GSK Investigational Site
Flagstaff, Arizona
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Sierra Vista, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Fayetteville, Arkansas
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Bakersfield, California
GSK Investigational Site
Cerritos, California
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Foothill Ranch, California
GSK Investigational Site
Fountain Valley, California
GSK Investigational Site
Garden Grove, California
GSK Investigational Site
Gold River, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Huntington Park, California
GSK Investigational Site
Lakewood, California
GSK Investigational Site
Lancaster, California
GSK Investigational Site
Loma Linda, California
GSK Investigational Site
Long Beach, California
Showing 40 of 1,611 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.